2,994
回編集
差分
ナビゲーションに移動
検索に移動
→Vaccine
*Pfs230
|}
===RTS, S/AS01===
*antigen: circumsporozoite protein (CSP)
*adjuvant: AS01
*4 doses
*phase 3
**efficacy: infant 26%, children 36%
**Lancet. 2015;386(9988):31-45
*WHO Malaria Vaccine Implementation Programme (MVIP) is ongoing
**Kenya, Ghana, Malawi
*efficacy wanes in time
**anti-CSP Ab titers wane
**White, Lancet Inf. Dis., 2015;15(12)1450-8
==症状==
